Our study has uncovered a novel regulatory mechanism of the PI3K/AKT/mTOR pathway, highlighting FAP as a promising biomarker for both diagnosis and prognosis of ccRCC, as well as a potential therapeutic target in ccRCC. Here, FAP is linked to nonpapillary renal cell carcinoma.